Abiopharma

🔍 Leonard Braden Michael (Executive)

Company: Outset Medical, Inc. (OM)

Report Date: 2026-05-08

Detailed Transactions and Holdings:

• Acquired 197,600 shares of Common Stock at $5.0 per share (Direct)
  Date: 2026-05-08 | Code: X | equity_swap_involved: 0 | shares_owned_after: 2,099,801.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 96,900 shares of Common Stock at $5.0 per share (Direct)
  Date: 2026-05-11 | Code: X | equity_swap_involved: 0 | shares_owned_after: 2,196,701.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 323,000 shares of Short Put Options (potential obligation to buy) at $5.0 per share (Derivative)
  Date: 2026-05-08 | Code: H | Expires: 2026-05-15 | Exercise: 2026-02-12 | shares_owned_after: 3,230.00 | Footnotes: F1
• Holds 110,000 shares of Short Put Options (potential obligation to buy) at $2.5 per share (Derivative)
  Date: 2026-05-08 | Code: H | Expires: 2026-05-15 | Exercise: 2026-02-12 | shares_owned_after: 1,100.00 | Footnotes: F1

Footnotes:

• F1: BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.